Entity

Time filter

Source Type


Rubio-Guerra A.F.,Hospital General de Ticoman | Rubio-Guerra A.F.,Mexican Group for Basic and Clinical Research in Internal Medicine | Cabrera-Miranda L.J.,Hospital General de Ticoman | Vargas-Robles H.,CINVESTAV | And 4 more authors.
Cardiology (Switzerland) | Year: 2013

Background: Hypoadiponectinemia and hyperresistinemia are associated with cardiovascular disease. The increase in the carotid intima-media thickness (CIMT) assessed by B-mode ultrasound has been directly associated with increased risk of myocardial infarction and stroke. Objective: To evaluate the correlation between adipokine levels with CIMT in hypertensive type 2 diabetic patients. Methods: Serum levels of adiponectin and resistin levels were measured by ELISA in 30 type 2 diabetic patients with never-treated hypertension and in age-matched healthy controls. The CIMT (B-mode color imaging of extracranial carotid arteries using high-resolution ultrasound) was also obtained. The relationship between adipokine levels and the adiponectin/resistin index with the CIMT was assessed by the Pearson correlation coefficient test. Results: Adiponectin was lower (p < 0.05), and resistin higher (p < 0.01) in patients than in controls, CIMT correlated positively with resistin (R = 0.45, p < 0.02) and the adiponectin/resistin index (R = 0.58, p < 0.001), but not with adiponectin levels (r =-0.11, p > 0.1) in patients. Whereas only adiponectin levels correlated-negatively-with CIMT (r =-0.39, p < 0.02) in controls. Conclusion: Our results shown that the adiponectin/resistin index seems to be more strongly associated with atherosclerosis than adipokine levels, and may be used as a reliable marker of cardiovascular risk in type 2 diabetic hypertensive patients. Copyright © 2013 S. Karger AG, Basel. Source


Rubio-Guerra A.F.,Mexican Group for Basic and Clinical Research in Internal Medicine | Vargas-Robles H.,CINVESTAV | Nuevo J.J.L.,Mexican Group for Basic and Clinical Research in Internal Medicine | Elizalde-Barrera C.I.,Mexican Group for Basic and Clinical Research in Internal Medicine | And 2 more authors.
Experimental and Clinical Cardiology | Year: 2012

BACKGROUND: Resistin levels are strongly correlated with insulin resistance and vascular inflammation. Type 2 diabetic and hypertensive patients have higher circulating levels of resistin, which is associated with endothelial dysfunction. OBJECTIVE: To compare the effect of trandolapril (T) and its fixed-dose combination with verapamil (FDTV) on resistin levels in hypertensive, type-2 diabetic patients. METHODS: Forty type-2 diabetic patients with never-treated hypertension were randomly assigned to two groups. One group received FDTV 2 mg/180 mg once per day; the other group received T 2 mg once per day. Study drugs were administered for three months in both groups. Resistin levels were measured using ELISA at the beginning of the study and at study end. Patients were evaluated monthly for blood pressure, fasting serum glucose levels and adverse events. Statistical analysis was performed using ANOVA. RESULTS: All patients experienced a significant reduction in blood pressure. Both therapeutic regimens reduced resistin levels; however, FDTV treatment resulted in a greater decrease in resistin levels (mean [± SD] 25.5±13 ng/mL to 17.2±10 ng/mL) when compared with T treatment (22.4±12 ng/mL to 18.5±8 ng/mL) (P<0.05). None of the patients experienced an adverse event. CONCLUSION: Results showed that FDTV resulted in a greater reduction in resistin levels than T treatment alone. © 2012 Pulsus Group Inc. Source


Duran-Salgado M.B.,Mexican Group for Basic and Clinical Research in Internal Medicine | Garro-Almendaro A.K.,Mexican Group for Basic and Clinical Research in Internal Medicine | Rubio-Guerra A.F.,Mexican Group for Basic and Clinical Research in Internal Medicine
Medicina Interna de Mexico | Year: 2015

Background: Hypertension and diabetes usually cluster in the same patient, antihypertensive agents modify that association. However, there are few studies about their combinations. Objective: To evaluate the effect of two combinations of losartan, with amlodipine or with hydrochlorothiazide, on glycemic and lipid values, in hypertensive subjects. Methods: A cross-sectional and comparative study done with hypertensive patients, who were randomized in 2 groups; group LA received losartan/amlodipine (100/5 mg) once a day, whereas LH group received losartan hydrochlorothiazide (100/12.5 mg) once a day, for 3 months. In all of them fasting serum glucose, and a lipid profile were performed at the beginning and end of the study, statistical analysis was performed with ANOVA. Results: All patients experienced a significant reduction of blood pressure to same extent (LA 155/94 to 123/79, LH 157/92 to 124/78 mmHg, p>0.05). In the LA group, serum glucose levels shown a significantly reduction, whereas in the LH group those values shown an increase, (LA 116 to 87 mg/dL, LH 120 to 126 mg/dL, p=0.002), in 3 patients those values went over the diagnostic figure of 125 mg/dL. Triglyceride levels decreased in the LA group, and rose in the LH patients, (203 to 174 mg/dL vs 208 to 210 mg/dL, p=0.02). We did not find significant changes in other lipoproteins. Conclusions: Both combinations decrease blood pressure values to same extent, however, LA combination shown favorable effects that reduce the metabolic risk in hypertensive patients. Source


Rubio-Guerra A.F.,Hospital General de Ticoman | Rubio-Guerra A.F.,Mexican Group for Basic and Clinical Research in Internal Medicine | Vargas-Robles H.,National Polytechnic Institute of Mexico | Suarez-Cuenca J.A.,Mexican Group for Basic and Clinical Research in Internal Medicine | And 7 more authors.
Medicina Interna de Mexico | Year: 2014

Background: Adipocytokines are adipocyte-secreted peptides that are involved in the pathways that lead to insulin resistance, inflammation and the development of cardiovascular disease. Objective: To evaluate the levels of the adipocytokines resistin and adiponectin in normotensive and hypertensive diabetic patients. Material and methods: Clinical and transversal study; circulating levels of resistin and adiponectin were measured by ELISA (RyDSystems Minneapolis) in 80 type-2 diabetic patients (40 normotensive and 40 hypertensive naïve to antihypertensive therapy), and in 40 normotensive non-diabetic subjects. Statistical analysis was performed with ANOVA. Results: We found a non-significantly decreased levels of resistin in control group when compared with diabetic normotensive patients, (13.5 vs 16.7 ng/mL p > 0.05); however, the coexistence of hypertension increased significantly (25.9 ng/mL p < 0.005) those values. We also observed increased values of adiponectin in control group when compared with diabetic normotensive patients (9.6 vs 7.5 μg/mL, p<0.05), but the coexistence of hypertension did not modified those values significantly (7.4 μg/dL p>0.05). Conclusions: Diabetic patients have increased levels of resistin and lower values of adiponectin when compared with non diabetic subjects, coexistence of hypertension increase the levels of resistin but do not modified adiponectin values, this may explain why diabetic patients (hypertensive or not) had more complications than normotensive patients. Source


Garcia S.,Institute Seguridad Y Servicios Sociales Of Los Trabajadores Del Estado | Lopez-Hernandez L.B.,Institute Seguridad Y Servicios Sociales Of Los Trabajadores Del Estado | Suarez-Cuenca J.A.,Institute Seguridad Y Servicios Sociales Of Los Trabajadores Del Estado | Suarez-Cuenca J.A.,Mexican Group for Basic and Clinical Research in Internal Medicine | And 11 more authors.
Folia Neuropathologica | Year: 2014

Genetic variants that confer susceptibility to Parkinson's disease (PD) show unbalanced distribution among different populations; genetic predisposition to either familial or sporadic forms of PD in Mexican-mestizo population has not been comprehensively studied. The aim of the present study was to analyze genetic variants in six PARK genes in PD patients. In total 381 individuals (173 patients, 208 controls) were genotyped for p.Gly2019Ser and p.Gly2385Arg variants of LRRK2. The p.Gly2019Ser variant was present in two patients and one healthy control; the p.Gly2385Arg variant was not found. In a subgroup of early-onset PD (EOPD), MLPA analysis was done for PARKIN (PARK2), PINK1 (PARK6), DJ-1 (PARK7), LRRK2 (PARK8), SNCA (PARK1/4) and ATP13A2 (PARK9). We found a heterozygous deletion of exon 2 in PARK2 in the youngest patient of the early-onset group, who showed limited response to antiparkinsonian therapy. Although the changes Gly2019Ser and Gly2385Arg of LRRK2 are associated with PD in different populations; they may be a rare cause of PD in our population. Novel population-specific variants may underlie PD susceptibility in Mexican mestizos. Our study suggests that the heterozygous deletion of exon 2 in the PARK2 gene is a risk factor for EOPD. Source

Discover hidden collaborations